<DOC>
	<DOCNO>NCT01399008</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability MBX-102 combination allopurinol compare allopurinol alone administer orally day four week gout patient inadequate hypouricemic response allopurinol alone .</brief_summary>
	<brief_title>Safety/Efficacy Study Evaluate MBX-102 Combination With Allopurinol Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>1 . Known gout patient ( per criterion American Rheumatism Association classification acute arthritis primary gout 1 . Patients take least 200 mg/day allopurinol sole ULT least two week sUA ≥ 6.5 mg/dL ≤ 12 mg/dL screen ≥ 6.0 mg/dL ≤ 12 mg/dL Week 1 ( Visit 2 ) randomization visit . OR 2 . Patients ULT take allopurinol &lt; 200 mg/day must sUA ≥ 8.0 mg/dL ≤ 12 mg/dL screen ≥ 6.0 mg/dL ≤ 12 mg/dL Week 1 ( Visit 2 ) randomization visit . 2 . Male female , 1875 year age screen 3 . All female patient must surgically sterile postmenopausal ( least 45 year age history menses least 2 year ; age history menses least six month serum FSH ≥ 40 mIU/mL ) partner undergone vasectomy must agree use two medically accept method contraception include barrier method ( see list Appendix 4 ) entire duration study unless report complete sexual abstinence . 4 . Female patient must pregnant lactating . 5 . Male patient female partner childbearing potential must agree use condom partner must use medically acceptable method contraception entire duration study . 6 . Estimated creatinine clearance ( CrCl ) CockcroftGault method ≥ 60 mL/min screen 7 . Serum creatinine value ≤ 1.1 mg/dL female ≤ 1.3 mg/dL male 8 . Liver function test ≤ 1.5X ULN AST , ALT Tbilirubin , ≤ 2X ULN ALP , ≤ 3X ULN GGT ; ≤ 3X ULN CK 9 . All clinical laboratory parameter must within normal limit consider clinically significant participation study . 10 . Electrocardiogram ( ECG ) must normal , abnormal , consider clinically significant participation study . 11 . Systolic blood pressure ≤ 160 mm Hg diastolic blood pressure ≤ 90 mm Hg ; know hypertensive patient control medication thiazide diuretic ( blood pressure [ BP ] read ) may include 1 . Treatment ULT allopurinol ( e.g. , probenecid , benzbromarone , febuxostat , pegloticase ) within 30 day Screening Visit 2 . Known suspected secondary hyperuricemia ( e.g . due myeloproliferative disorder , organ transplant ) 3 . Diagnosis xanthinuria 4 . History document suspected kidney stone 5 . Known infection HIV history viral hepatitis type B C 6 . History illicit drug alcohol abuse within 1 year screen 7 . History significant pulmonary disease , upper GI bleeding , document peptic ulcer disease ( unless know H. pylori infection treat successfully without recurrence ) , nephrotic syndrome within three year screen 8 . History stroke , TIA , acute MI , congestive heart failure ( NYHA Class IIIV ) , angina pectoris , coronary intervention procedure ( include limit angioplasty , stent placement , coronary revascularization ) , low extremity bypass procedure , systemic intracoronary fibrinolytic therapy within five year screen 9 . Malignancy ( except treat basal cell carcinoma ) within five year screen 10 . BMI &gt; 42 kg/m2 11 . Current expect requirement anticoagulant therapy ( except aspirin ≤ 325 mg/day ) 12 . Rheumatoid arthritis autoimmune disease require ongoing treatment 13 . Current expect treatment potent CYP3A4 inhibitor ( See Appendix 6 ) , cytotoxic agent ( azathioprine , mercaptopurine , cyclosporine , cyclophosphamide , etc . ) , ranolazine , digoxin , theophylline , sulphonylureas , thiazolidinediones , diuretic , atypical antipsychotic agent , ampicillin , amoxicillin phenytoin 14 . Chronic treatment NSAIDs ( use treat acute flare permit ) . 15 . Current expect treatment systemic corticosteroid ( except topical , ophthalmic , intraarticular , inhale dose &lt; 1600 μg/day ) treat acute flare 16 . Known hypersensitivity allopurinol , colchicine , aspirin 17 . Treatment investigational therapy within 30 day prior screen , patient receive least one dose study drug enrol previous concomitant MBX102 trial 18 . Any condition compromise ability patient provide inform consent comply objectives procedure protocol , judge investigator and/or medical monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hyperuricemia</keyword>
</DOC>